A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).

Conditions: Healthy Interventions: Drug: Treatment A: BGF MDI HFA; Drug: Treatment B: BGF MDI HFO; Drug: Treatment C: BGF MDI HFO; Device: AeroChamber Plus Flow-Vu Spacer Sponsors: AstraZeneca; Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials